Sell-rated reports

287 tickers rated Sell
NewestHighest Score Ranks all reports in this rating group by score, highest first.
NewAmsterdam Pharma Company N.V.
NAMS·Healthcare
C ★★Sell
Current$19.00
Nov 10, 2026

NewAmsterdam Pharma's European approval and advanced obicetrapib trials create substantial commercial potential, but unproven recurring royalties, persistent cash burn, and cardiovascular outcomes uncertainty constrain the investment case.

Score
60
Algonquin Power & Utilities Corp.
AQN·Utilities
C ★★Sell
Current$5.52
Nov 9, 2026

Algonquin's regulated utility restructuring offers a path toward more predictable earnings and improved capital discipline, but elevated debt, wildfire costs, and weak free cash flow continue to constrain shareholder returns.

Score
60
Core Scientific, Inc.
CORZ·Technology
C ★★Sell
Current$11.76
Nov 8, 2026

Core Scientific offers exceptional AI data center revenue growth backed by substantial contracted capacity, but heavy capital spending, leverage and customer concentration threaten sustainable shareholder returns.

Score
60
Viasat, Inc.
VSAT·Technology
C ★★Sell
Current$63.95
Nov 8, 2026

Viasat could benefit from expanding defense demand and monetizing its newly deployed satellite capacity, but weak capital returns, commercial connectivity competition, and substantial leverage undermine the current investment case.

Score
60
Caris Life Sciences, Inc.
CAI·Healthcare
C ★★Sell
Current$25.23
Nov 7, 2026

Caris Life Sciences offers long-term growth through precision oncology and proprietary genomic data, but deteriorating cash conversion, rising operating costs and demanding valuation undermine its near-term investment appeal.

Score
60
TransAlta Corporation
TAC·Utilities
C ★★Sell
Current$13.12
Nov 6, 2026

TransAlta could benefit from contracted gas generation and rising data-center electricity demand, but declining free cash flow, substantial leverage and elevated historical valuation limit its current investment appeal.

Score
60
Denali Therapeutics Inc.
DNLI·Healthcare
C ★★Sell
Current$19.72
Nov 6, 2026

Denali's validated blood-brain barrier platform and accelerating AVLAYAH launch offer significant long-term growth potential, but persistent cash burn, concentrated revenue, and demanding execution expectations constrain near-term investment appeal.

Score
60
Vornado Realty Trust
VNO·Real Estate
C ★★Sell
Current$36.29
Nov 5, 2026

Vornado's premium Manhattan portfolio and improving leasing economics offer turnaround potential, but high leverage, redevelopment spending, and an elevated historical valuation limit the margin of safety.

Score
60
Life Time Group Holdings, Inc.
LTH·Consumer Discretionary
C ★★Sell
Current$44.61
Nov 2, 2026

Life Time's premium athletic clubs offer durable membership growth and improving operating leverage, but its demanding valuation, heavy development spending, and negative free cash flow constrain shareholder returns.

Score
60
UFP Industries, Inc.
UFPI·Materials
C ★★Sell
Current$81.92
Nov 2, 2026

UFP Industries has strong liquidity, valuable manufacturing franchises, and acquisition-driven recovery potential, but persistent freight inflation, weak capital returns, and demanding normalized cash-flow expectations limit near-term upside.

Score
60